Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good news on THTHF, could fly .
http://biz.yahoo.com/bw/031030/305049_1.html
Skoobyfl1, I think you missed it on this post of yours. Might have to wait another week or two to get to the one dollar level. Not worried though, the timing is just off .
====================================================
Posted by: skoobyfl1
In reply to: Locus who wrote msg# 2371 Date:10/27/2003 2:27:13 PM
Post #of 2472
You are not the only one trying to get cheaper prices on the stock. I have a few friends that have been trying to buy it and they will not drop the price. I'm thinking if you and they cannot get it at that price, there has to be more people also trying. Support is the name of the game there, we have and are holding steady on a low volume. Nobody is willing to give up their shares. The only thing that will change is the buyers will end up chasing this stock up past a dollar and beyond soon. This will be the last week below a $1.00.
NEOM could move on this news:
http://biz.yahoo.com/bw/031030/305084_1.html
The actual article from TopSmallCaps.com's buy recommendation:
CytoGenix Inc. is a biopharmaceutical company headquartered in Houston, Texas that develops molecular gene therapeutic medicine products using a proprietary gene silencing (blocking) technology. CytoGenix is developing therapeutic products for herpes, psoriasis and inflammation. The Company also conducts pre clinical research in cancer and anti bacterial genes.
Drug target validation is a technology aimed at proving that DNA, RNA, or a protein molecule is directly involved in a disease process. Pharmaceutical industry experts agree that drug target validation is the most critical challenge facing large pharmaceutical companies. Given the vast number of potential drug targets that genomics has delivered, it has become crucial to pinpoint those targets that are most likely to be amenable to therapeutic intervention. Thus, target validation technologies are in strong demand. Drug target validation technology allows large pharmaceutical companies the opportunity to significantly reduce new drug discovery costs as well as reducing failure rates.
Technology & Market
CytoGenix has made great strides in developing a core DNA expression technology and using it to develop therapeutic products. The business model that CYGX adheres to is a two-pronged strategy - generating revenue by providing drug target validation services while forming product development partnerships with pharmaceutical and biotechnology companies.
Most diseases are the results of harmful proteins that are produced by genes that are faulty. Infectious agents, such as viruses, invade cells and take control of the DNA apparatus as a way of reproducing and damaging cells. Genetic predisposition or environmental factors can also trigger faulty DNA that can cause many disorders such as Cancer and Alzheimer's disease. Most pharmacological agents act by chemically signaling cells to interrupt or reduce production of the “bad” protein, or by binding to and adjusting the structure of a protein to ameliorate its activity. Traditionally, these agents were discovered by accident. Most drugs are systemic and usually cause side effects. Aside from vaccines, few of today's drugs are curative or preventative.
It is estimated that there are approximately 35,000 human genes, each coding for a different protein. These genes may suffer mutations leading to production of faulty or harmful proteins. Although the molecular nature of many diseases is not yet understood, thousands of researchers in academia, government and industry are working to identify and characterize disease related proteins and genes. Once these disease gene targets are identified, validated, and understood as to their function, then therapeutic agents can be designed to halt, reduce, or correct their disease causing action.
In its basic form, the protein generating mechanism of cells is a biochemical process that starts with the transcription of DNA instructions into messenger RNA (mRNA) followed by the translation of the mRNA into the building blocks of proteins. CytoGenix proprietary technology interrupts the translation of mRNA through a novel method of introducing specific DNA instructions that direct the cell's machinery to cancel translation of the mRNA of a specified gene into a protein. By harnessing the cell's natural internal DNA machinery to replicate the gene blocking instructions, this technology overcomes the limitation of other gene medicine approaches that require the introduction of large concentrations of DNA into the cells from external sources. This technology enables and enhances the performance of gene medicine methods such as antisense and triplex.It also has great promise as a platform for the recently discovered DNA enzyme method.This fundamental molecular control in cells has the potential to be widely applied for the development of therapeutic agents against certain cancers, autoimmune and infectious diseases.
CytoGenix is led by a highly experienced business and scientific management team. A 50% Ph.D. level staff along with outside experts in STD, dermatology, microbiology and gene therapy. Cytogenix is solid with well established proof of concept, published papers in scientific literature, one issued U.S. Patent, approximately 40 U.S. and foreign pending patent applications, and a new patent for anti bacterial filed in June, 2003. The company provides versatile technology that works on many disease targets. CYGX is currently working on a pipeline of three products and five indications addressing a $3 to $4 billion dollar market, including Herpes 1 & 2, Psoriasis, Shingles, and Contact dermatitis.
Recent Developments
On June 18, 2003 the company announced that pre clinical trials show CYGX's anti-genital herpes DNA formulation virtually eliminates the virus. The US Center for Disease Control has classified genital herpes as an epidemic, a serious health problem and reports that "Genital herpes simplex virus type two (HSV2) is one of the most common sexually transmitted diseases in the United States, with as many as one million people becoming infected each year." The data from recent laboratory studies show a 100-fold decrease in the viral load of cells treated with CYGX' DNA formulation as compared to untreated cells when challenged by HSV 2 virus. Industry estimates place the market for herpes Rx products in excess of $1.5 billion dollars.
In July 2003, the Company announced that it licensed the Anti-Herpes DNA formulation for manufacture and distribution in The Peoples Republic of China. Soon after, the licensee exercised a similar license for India.
In August 2003, the Company completed an agreement with BioZone Laboratories, Inc. to investigate the synergy of their technologies to develop new more effective skin delivery formulations. BioZone has developed a new technology to encapsulate a variety of drugs, proteins and peptides at a fraction of the cost of conventional methods.
Also in August, the official journal of the International Society for Cancer Gene Therapy, Cancer Gene Therapy, published the results of a study conducted by CytoGenix Vice President of Research and Development, Dr. Yin Chen along with independent outside collaborators. The study showed the inhibition of growth in lung, breast, and cervical cancer cells when treated with Company’s ssDNA expression system against target cancer related proteins.
Throughout September 2003, to the present CytoGenix has gained attention from the scientific and financial communities. The company is dedicated to creating human benefit and investor value by developing therapeutic agents that regulate genes to cure the root cause of disease rather than ameliorate symptoms. In addition to products in pre clinical development, CytoGenix supports a program of cancer research conducted in several medical research centers. Cytogenix owns patents for its core technology and has over 40 international or US pending patents.
Outlook
Upon successful completion of phase I/II of clinical trials, CYGX intends to seek distribution agreements with domestic and foreign pharmaceutical companies. These agreements will fund the remaining clinical trials and FDA marketing approval steps. A mathematical valuation model produced by Joachim M. Gruel in July 2002, The R&D value conundrum, allows for the following assumptions with respect to CYGX' anti herpes cream from Phase I through to NDA Registration.
Phase I:
Human safety tests performed on 20-80 healthy adults over 6 months with an approximate cost of $500,000.00. A success probability of 25%, (taken from averages of the experience of many pharmaceutical products.) 20 year net cash flow $2 billion dollars. Discounted present value $264,850,000.
Phase II:
Safety and efficacy trials performed on about 200 people over 12 months with an approximate cost of $1.5 million dollars. A success probability of 45%. 20 year net cash flow $2 billion dollars. Discounted present value $476,730,000.
Phase III:
Multi center clinical trials on about 2000 people over 24 months with an approximate cost of $4 million dollars. A success probability of 70%. 20 year net cash flow $2 billion dollars. Discounted present value $741,580,000.00.
Over the next 24 months CYGX intends to accomplish the following milestones:
• Complete pre clinical trials for Herpes, Contact Dermatitis, Psoriasis & Sepsis antibacterial
• Receive FDA approval for human trials for Herpes, Contact Dermatitis & Psoriasis
• Conduct safety and efficacy (phase I and II) trials for Herpes, Contact Dermatitis & Psoriasis
• Develop sepsis antibacterial
• Develop systemic delivery system
• Develop antiseptic agents not susceptible to bacterial resistance.
Conclusion
CytoGenix’ Genetic Therapy promises dramatic change from treating symptoms to eliminating the disease. CytoGenix is positioned to service market share created by the growing demand for drug target validation through delivery of validation services. The company expects to generate revenue that can offset the cost of developing its own line of proprietary therapeutic products.
CytoGenix has a patented core technology exploiting the manipulation of RNA to produce gene-based therapeutics based on gene-silencing, RNA interference, and other gene modification applications. The company is a newcomer on the academic research scene, with its first patent issuing in 2000. The story is largely unknown among investors. However, our scan of patent applications in this area clearly indicates the cusp of a tidal wave of research and development activity in a variety of RNA directed therapeutic strategies. While CytoGenix is young technically, and currently has limited financial resources, its core technology has been developed to the point where commercial target validation tools are available and pre-clinical toxicology and studies can proceed.
CytoGenix’ technology provides a unique alternative to the current "state-of-the-art" and standard practice of vector gene therapies, since it presents a valid means by which to circumvent or ameliorate many existing issues. Though highly speculative due to the limited financial resources at hand, we view the company as a promising member of third-generation genomics therapy companies.
Disclaimer
Chipped, that would be nice. Whatever news we do get, I hope it is very positive which will help move the stock. I like the company and the products. Some news on the distribution of anti-herpes topical cream to India would be a nice as far as the public beginning to believe the company may be one to consider for long term growth.
When this current situation "Both countries are experiencing rapidly increasing incidences of sexually transmitted diseases (STDs). With a total 2.3 billion people, India and China have about 40% of world's population. Based on U.S. genital infection rates of 1 in 4 adults, an estimated 575,000,000 people in China and India could be infected." is realized by the investment community and the company is able to announce sales, the stock will become very attractive for the big boys.
http://biz.yahoo.com/bw/030826/265403_1.html
Chipped, CYGX holding strong and steady. I'm believe we might be getting some news within the next two weeks. JMO.
THTHF - on the radar screen. Another high volume day, it's about ready to pop .
chipped, what's the latest on CYGX?
OT: Dream, you've got mail.
Hi Peach, see post #2 on this thread by chipped.
Rick,regarding your comment "Why isn't everyone including the institutions in CYGX = They don't know about it yet - their learning as time pasts and when they learn of CYGX's value you will see great improvement in PPS." The institutions don't look at anything less than a penny. CYGX has to reach the $1.00 or better and get listed on the NASDAQ, then you will see institutions looking at it. Per the last PR, the company president has already presented CYGX's products, company strategy and business plans. So, some of the big boys are aware of the company. With more news on the distribution of the company's products, and the PPS will take off. Hopefully, we get some of this news soon as skooby and chipped have implied. GYGX has so much potential with the anti-herpes product alone, and that in China and India. When word gets around that the product is effective, more people will buy the stock.
CYGX is slowly swinging north . Some good is coming very soon.
I hope it's juicy, but like you, I heard some good news is coming very soon.
Dream, you have e-mail.
ISYN- She's alive! Wheeeeeeeeeee
ISYN - It's about time it went the right direction.
Dream, please write me at bram12345@hotmail.com
ISYN - That has got to be the biggest POS I've come across in awhile.
Let's see if todays news moves ISYN north.
http://biz.yahoo.com/bw/031001/15234_1.html
Atlanta, thanks for the heads up. ISYN should start moving soon. I understand there are some PRs coming very soon, don't know exactly what, but that they will be soon. With DOMS off the offer, ISYN should begin its up leg anyday. .
Excel, Not to burst your bubble, but I'm not too sure about that. I think AMEP still could drop some more.
ISYN - Pounding on the table for you to get it. It's ready for a bounce IMHO
ISYN - Heard more news may be coming out this week (possibly two, not promising, just stating what I heard). Heck, it's cheap enough.
If the S-8 would finish up, this one could move hard. I'm in .
The market seems to like yesterday's ISYN news .
http://biz.yahoo.com/prnews/030925/nyth147_1.html
AMEP and ISYN both on the move today with yesterday's after the bell news .
http://biz.yahoo.com/bw/030925/255595_1.html
http://biz.yahoo.com/prnews/030925/nyth147_1.html
Hey i_like_bb_stock, I know you don't like ISYN, but good news is good news, no matter how you slice it. The big one which will probably be next week) will be when the company releases the news on "Workplace". Lots of shares out there, but the stock is cheap. .
Better to get in now while it is this low. With the big news coming soon, this one could take off JMO .
Hack, does this answer your PM to me? Here's the link to AMEP news. Sorry, I'm not a paid subscriber, so I couldn't reply to you. But news like I said .
http://www.newsalert.com/bin/story?StoryId=Cp3jOqbKbytu1otu&FQ=c%25AMEP%20&Nav=qr-re-rediges...
Buzz, laugh if you must, but I'm in ISYN. I think she might be ready for a pop .
GFYTDR, don't know about CYGX, but AMEP should run as we near the close. Most stocks run 2 to 3 days when good news is released. With this great news on AMEP, it's very possible we could reach the 20 cent level in a week or two. Don't forget, there are many more PRs coming soon.
Hey Dream, when is your next pick coming? You've had some great ones, but have been rather quite lately .
Oh, and one last thing on AMEP. There is more news coming by end of the month. I don't know the timing, but there is definitely more news coming .
GFYTDR, Regarding AMEP, I believe there is a strong possibility of it breaking out later today. First, there has to be dip, then look for the stock to move up.
Once the news is absorbed by other investors/speculators, they will realize that the stock is cheap at these prices. Consider that the production volume increases 10 fold with the additive and the grade changes from sour crude to sweet, when that sinks in, the stock is going to soar.
AMEP - slowing, but surely . More news coming before the month's over too
.
AMEP - Five minutes into trading and volume already 1 million . It should move up steady through out the day.
AMEP primed to move up much more in the near future. Don't forget, there is more news coming folks too.
AMEP news! http://biz.yahoo.com/pz/030923/45463.html
“The two oil wells have a history of producing one half to one barrel of oil per day for the last ten years. After treatment with the heavy oil additive, the two oil wells have dramatically increased oil production, one well making over ten (10) barrels of oil per day and the second well making over twelve (12) barrels of oil per day.”
American Energy Production Inc. Announces Dramatic Results From First Test Of Heavy Oil Additive
Tuesday September 23, 4:15 pm ET
MINERAL WELLS, Texas, Sept. 23, 2003 (PRIMEZONE) -- American Energy Production Inc. (OTC BB:AMEP.OB - News) announced today the results from the treating and testing of two heavy oil Olmas formation wells on lease properties American Energy Production Inc. is negotiating to purchase. The two oil wells have a history of producing one half to one barrel of oil per day for the last ten years. After treatment with the heavy oil additive, the two oil wells have dramatically increased oil production, one well making over ten (10) barrels of oil per day and the second well making over twelve (12) barrels of oil per day. This is a 2000% increase from the past production history of the two oil wells. AMEP realizes the wells may not sustain this increased production rate, but any production over 1 barrel per day is a vast improvement. Not only did the wells increase in oil production, the oil additive changed the physical structure of the oil, changing the gravity of the oil from 20 gravity to approximately 35 gravity. The oil usually contains 1.7% sulfur content and now the smell of sulfur is barely noticeable. Changing the gravity and removing the sulfur from the oil is extremely important price wise for the sale of this particular oil. This Olmas formation oil usually brings $2.00 to $3.00 per barrel less than West Texas sweet crude oil. The oil additive will possibly change the oil from South Texas sour crude to sweet crude. AMEP is sending samples of the treated oil to be tested for viscosity and content of sulfur to lab testing facilities in Alice, Texas. The Company will release the results of the test in the future.
American Energy Production Inc. will proceed with treatment and testing of four more oil wells immediately with the new heavy oil additive. This lease has 193 oil wells equipped and capable of producing oil. The potential proven produceable oil reserves on the lease is 62,000,000 barrels, and the Company believes only about 2% to 4% of these oil reserves have been produced over the last 20 years. AMEP plans to eventually treat all 193 of the oil wells and then have an ongoing treatment program.
American Energy Production Inc. is in the process of buying pump trucks and transports to treat the oil wells. This will make the Company self sufficient instead of relying on outside pumping services.
Charles Bitters, President of AMEP, said ``This new heavy oil additive is very interesting and at this time has the potential to radically change the way secondary recovery of heavy oil is done in the future. However, it will take more treating and testing to refine the most efficient treatment methods.'
About American Energy Production, Inc.
American Energy Production, Inc. is an oil and gas lease acquisition company. The Company will specialize in acquiring oil and gas leases that have potential for increased oil and natural gas production utilizing new technologies, well work-overs and fracture stimulation systems. American Energy Production, Inc. will acquire oil and gas leases that have proven reserves. The Company will initiate developmental drilling programs to drill new wells on these leases and, if successful, will add oil and gas reserves to the acquired property. American Energy Production, Inc. is involved in three areas of oil and gas operations: Leasing Programs, Production Acquisitions and Drilling with new technologies. American Energy Production, Inc.'s main objective is to find oil and gas leases with upside potential for enhanced production. The company does this by utilizing the following rules: 1) leases, 2) geology, 3) engineering and 4) mapping from 3-D seismic.
Statements contained in this release, which are not historical facts, may be considered ``forward-looking statements' and are based on current expectations and the current economic environment. We caution the reader that such forward-looking statements are not guarantees of future performance. Unknown risk, uncertainties, as well as other uncontrollable or unknown factors could cause actual results to materially differ from the result, performance, or expectations exposed or implied by such forward-looking statements.
Contact:
American Energy Production Inc.
I/R Plus
John DeLisa
(866) 910-2323
More NEOM news:
http://biz.yahoo.com/bw/030923/235087_1.html
European Launch of New 'Killer Wireless App' for Nokia Camera Cell Phones to be Engineered by 12snap UK, Leading Cell Phone Marketing Agency in Europe
Tuesday September 23, 8:32 am ET
LONDON & FT. MYERS, Fla.--(BUSINESS WIRE)--Sept. 23, 2003--The European launch of a new "killer wireless app" for Nokia® Camera Cell Phones from NeoMedia Technologies, Inc. (NASDAQ BB: NEOM - News) will be engineered by 12snap U.K. Ltd., a leading advertising agency in Europe focused on cell phone marketing.
Chas Fritz, chairman of NeoMedia, said his company signed an LOI with 12snap outlining a collaborative agreement for the launch and marketing of the technology introduced earlier this month (see "NeoMedia's New 'Killer Wireless App' for Nokia Camera Cell Phones Turns Internationally-Popular Toys Into Internet-Enabled Business Tools," Business Wire, Sept. 8). 12snap will also promote and support BigGig Strategies, NeoMedia's European agent (see "New Internet Link from Mobile Camera Phones 'Bigger Than Text Messaging' says David Foster-Lyons, Managing Director of Big Gig Strategies," Business Wire, Sept. 9).
'Thrilled to be Launching PaperClick'
"As 12snap is a creative force which thrives on innovative concepts and technologies, we are thrilled to be launching PaperClick in Europe," said Martin Copus, its managing director. "12snap's launch, support and involvement with PaperClick will cover the U.K. and Europe, and utilize the mobile/cell channel itself. The medium and its ability to innovate really is the message here," he said, citing a recent campaign for Walkers® Snack Foods (Frito-Lay®), the largest-ever text messaging promotion in the U.K., incorporating, for the first time, direct-to-phone text crediting.
PaperClick and PaperClick for Camera Cell Phones
Pioneered and patented by NeoMedia, PaperClick reads and decodes bar codes to link users to the Internet, providing information and enabling m-commerce. It employs a standard browser, optional client software, and a network of online service and applications servers transparent to the user.
PaperClick for Camera Cell Phones(TM), available first for the Nokia 3650, reads UPC/EAN and other bar codes through the camera to link the user quickly and directly to corresponding the Web site or information. PaperClick enables m-commerce, letting companies and product/brand managers gain immediate and direct access to readers/shoppers, who need only take a picture with the camera phone to be automatically connected to tailored on-line Web information.
PaperClick installs via the phone's infra red (IR) port, the BlueTooth® wireless network, or by download using its built-in browser, requiring only 11.3KB of memory. With software currently implemented for the Symbian(TM) operating system, it supports UPC-A, UPC-E, EAN-13, ISBN and PaperClick codes. A previous version of PaperClick runs on Palm Pilot® PDA's.
David Foster-Lyons, managing director of BigGig Strategies, said he "tracked PaperClick for several years, believing all it needed to be incredibly successful was the right device to unleash its amazing power. Now we have the mobile/cell picture phone, which happened by chance, much as the mobile text market in Europe emerged almost overnight by chance to become a $42 billion industry." "I believe," he said, "PaperClick for Camera Cell Phones will be bigger than text messaging!"
Overwhelming Reception for New Technology
NeoMedia's Fritz called the marketplace's reception of PaperClick for Camera Cell Phones "overwhelming". "From its introduction two weeks ago to last week's Symbian® Partner Event in San Francisco, as a newly-named Symbian Platinum Partner® we demonstrated our technology, PaperClick has been called 'the killer wireless app for cell phones," he said.
"We are very excited about PaperClick's reception in the cell phone marketplace," he said. "NeoMedia's patented technologies are in demand, and we are aggressively working to sell licenses and ensure that our shareholders' investment in patents and other IP is protected and a viable generator of income."
About NeoMedia Technologies
NeoMedia Technologies, Inc. (www.neom.com), is an innovator and international leader in print-to-Internet and other technologies which make information faster and easier to access, with expertise in homeland security and e-authentication applications. NeoMedia markets services which link physical information and objects to the Internet under the PaperClick and PaperClick For Cell Phones trademarks, and its Systems Integration Group specializes in Open and Storage System solutions and automating print production operations. NeoMedia has announced plans to acquire and merge with Loch Energy, Inc., of Houston, an energy company with proven and probable reserves of 13.67 million barrels of oil, and Secure Source Technologies, Inc., of Silver Spring, Maryland, a provider of security solutions and a pioneer in covert security technology for the manufacturing and financial services industries.
About 12snap
12snap (www.12snap.com) is an award-winning advertising agency focused on mobile channels. Providing campaign concept realization and delivery, 12snap has developed innovative and effective marketing and CRM programs for top global brands, including McDonald's®, Procter & Gamble®, Stella Artois®, Cadbury's®, L'Oreal® and MTV® 12snap is the first mobile marketing agency to win a prestigious Cannes Lion award through its work for Sony® PlayStation® 2.
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement
PaperClick, PaperClick for Nokia Camera Phones and PaperClick for Camera Cell Phones are trademarks of NeoMedia Technologies, Inc. Other trademarks are properties of their respective owners.
--------------------------------------------------------------------------------
Contact:
NeoMedia Technologies
Charles T. Jensen, 239-337-3434
cjensen@neom.com
or
12snap U.K. Ltd.
Martin N. Copus, +44-207-534-7300
martin.copus@12snap.com
or
The Kaminer Group
David A. Kaminer, 914-684-1934
dkaminer@kamgrp.com
--------------------------------------------------------------------------------
Source: NeoMedia Technologies, Inc.
AMEP getting ready to do the dance. News coming anyday, very possible tomorrow after the bell.
Buzz, yes AMEP is moving nice and steady prior to this weeks news. News is expected to be positive (stated by the company, not me), and when it comes, the strong will move fast.
http://finance.yahoo.com/q?s=AMEP.OB&d=t
This week's news will only be one of many coming our way, the first one will be on the oil drilling additive, which could be start the stock on its way up. Also, cancellation of 8% of the stock coming soon too.
Some notes from the news links are in this poster's message:
By: rbitulsa
20 Sep 2003, 06:27 PM EDT
Newbies: Reasons to consider AMEP, ASAP:
1) Press release coming between now and Wednesday expected to announce positive test results on a new additive which helps stimulate oil production in producing wells. Also anticipating announcement of completion of distribution rights for this new additive. Also, anticipating announcement of more wells being brought on-line soon.
2) Sept. 16, 2003: a) "oil production...began today". b) "American Energy Production Inc. will announce, in a few days, the results of the testing on the heavy oil additive on the South Texas oil leases."
3) Sept. 4, 2003: "things have been progressing as planned, to date"
4) Aug. 21, 2003: a) "Company is in Final Stage Negotiations for Distribution Rights on Oil Well Additive". b) own proven recoverable developed non-producing reserves [in Comanche/Eastland County, Texas
consisting] of 2,232,522, barrels of oil and 2.985 billion cubic feet of natural gas. The gross Future Net Revenue of the oil and natural gas reserves is $68,516,680."
5) June 25, 2003: "working with counsel on the Recovery and cancellation of 5,406,500 common shares, thus reducing the issued and outstanding by an approximate 8%.
6) June 14, 2003: a) "signed a Letter Of Intent with Production Resources Inc., on June 24, 2003 to purchase substantially all of the oil properties owned by the company in Medina County, Texas. The oil leases cover more than 5,000 acres and has a long history
of oil production through three producing horizons, which have an estimated 62,000,000 barrels of proven recoverable oil reserves...192 fully equipped oil wells capable of producing several hundred thousand dollars per month with new technology and stimulation procedures that will be incorporated into oil operations. The oilfield will be able to produce to its maximum potential using the Company's newly acquired technology, which the Company is not
at liberty to discuss in detail at this time." "...the bond is [already] in place to operate up to 99 wells." "expect [four of these] wells to be operational and producing revenues for our third quarter.
AMEP - News this week, if positive as expected, then we go into the teens .